Until recently, neoadjuvant chemoradiation studies have been performed using cisplatin/5-FU based regimens with a variation in dose and a variation in radiotherapy schemes.
A tacrolimus based regimen (with adjusted dose according to patient's trough serum level) is the main immunosuppression protocol used in this study.
5 According to Büchler et al, an SRL based regimen with mycophenolate mofetil (CellCept®) was as effective as CsA based regimen in terms of graft and patient survival and maintaining low rate of acute rejection (AR).
The remaining patients received a taxane and/or platinum based regimen, with the addition of other agents.
Gemcitabine based regimen with lower dose settings resulted in acceptable toxicity and good compliance and in combination with hypofractionation resulted in comparable overall and disease-free survival.
Within the past decade, many Phase II trials have been conducted to compare docetaxel based regimens with mitoxantrone plus prednisone in an attempt to demonstrate improvement with respect to standard of care.
Data on urinary protein excretion were available for 37 161 individuals, mostly from trials that compared ACE inhibitor based regimens with placebo.
In order to get further improvements in the last decades many studies have tested multimodality treatment schedules incorporating chemotherapy (CT) with nitrosourea based regimens, with questionable survival advantages [ 1– 6].
Four patients have been treated with a semustine based regimen, one with a combination of vinblastine, bleomycin and cisplatin, and the last one with dianthydrogalacticol. Petit et al. [ 5] described 5 out of 160 patients who went into long-term remission 7 years after fotemustine chemotherapy followed by surgery.
The standard of care for patients with advanced epithelial ovarian carcinoma involves an attempt at optimal cytoreductive surgery followed by chemotherapy with a platinum based regimen in combination with paclitaxel.
For the secondary outcomes, there was heterogeneity in the effect of ACE inhibitor based regimens against heart failure compared with calcium antagonist based regimen by eGFR, with evidence of greater benefit for ACE inhibitors among participants with eGFR >60 (appendix table 5).
